Eventide Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

Eventide Asset Management’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$279K	Buy	+2,795	New	+$247K	﹤0.01%	253
2023 Q4	–	Sell	-320,000	Closed	-$5.34M	–	165
2023 Q3	$5.34M	Hold	320,000	–	–	0.1%	134
2023 Q2	$8.84M	Buy	+320,000	New	+$8.01M	0.15%	123
2018 Q1	–	Sell	-275,000	Closed	-$5.72M	–	148
2017 Q4	$5.72M	Buy	275,000 +150,000	+120%	+$2.66M	0.3%	81
2017 Q3	$2.21M	Hold	125,000	–	–	0.13%	100
2017 Q2	$1.41M	Buy	+125,000	New	+$1.34M	0.09%	103

Other funds holding PTGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Eventide Asset Management's PTGX Position: Q1 2026 in Review

Eventide Asset Management opened a new position in Protagonist Therapeutics (PTGX) in Q1 2026: 2,795 shares worth $279K. The stake represents ﹤0.01% of the portfolio and ranks #253 among its holdings. This is a return to the name: Eventide Asset Management previously reported a position in PTGX as recently as Q3 2023.

Eventide Asset Management first reported a position in PTGX in Q2 2017 and has held it in 6 quarters since. The position peaked at $8.84M in Q2 2023. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

Eventide Asset Management held 2,795 shares of Protagonist Therapeutics worth $279K as of Q1 2026.
Protagonist Therapeutics was a new Eventide Asset Management position in Q1 2026.
Protagonist Therapeutics made up ﹤0.01% of Eventide Asset Management's portfolio in Q1 2026, its #253 holding.
Eventide Asset Management first reported a position in Protagonist Therapeutics in Q2 2017 and has held it in 6 quarters since.
Eventide Asset Management's Protagonist Therapeutics position peaked at $8.84M in Q2 2023.
317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Eventide Asset Management's 13F filing for Q1 2026, filed 15 May 2026.